Allogeneic hematopoietic cell transplantation following reduced intensity conditioning for treatment of myelofibrosis.

Allogeneic hematopoietic cell transplantation following reduced intensity conditioning for treatment of myelofibrosis. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Allogeneic hematopoietic cell transplantation following reduced intensity conditioning for treatment of myelofibrosis. Abstract Text:

David S Snyder,Joycelynne Palmer,Anthony S Stein,Vinod Pullarkat,Firoozeh Sahebi,Sandra Cohen,Nayana Vora,Karl Gaal,Ryo Nakamura,Stephen J Forman,

This report describes our experience with reduced intensity conditioning (RIC) allogeneic hematopoietic cell transplantation (HCT) using matched sibling and unrelated donors (MUDs) for treatment of myelofibrosis (MF). Nine patients with MF (median age, 54 years) were treated with RIC allogeneic HCT using MUDs for 7 of the 9 patients and sibling donors for 2 patients. By the Lille classification, 4 patients were characterized as having high risk, 4 as having intermediate risk, and 1 as having low risk. The RIC regimen consisted of fludarabine and a single dose of total body irradiation for the first patient and fludarabine/melphalan for the remaining 8 patients. Granulocyte colony-stimulating factor-primed peripheral blood stem cells (PBSCs) were used for all but 1 patient who received a total of 3 products because of graft failure, of which 2 were bone marrow cells and the third was PBSCs. Prophylaxis against graft-versus-host disease consisted of cyclosporin/mycophenolate with or without methotrexate. Seven patients were successfully engrafted with white blood cells, with an absolute neutrophil count > or =500 by a median of day +15 (range, 10-21 days). At the time of final fluorescence in situ hybridization and/or short tandem repeat analysis, 8 of 9 patients were chimeric, with 96%-100% donor cells and/or DNA. Five of the 9 patients were alive at the time of final contact, with a median follow-up of 32.2 months for the living patients. Overall survival probability at 1 year was 55.6% (95% confidence interval, 31.3%-77.4%). These results suggest that RIC MUD HCT using PBSCs can be an effective treatment for older patients with MF.

Allogeneic hematopoietic cell transplantation following reduced intensity conditioning for treatment of myelofibrosis. Publishing Authors By Initials

DS Snyder,J Palmer,AS Stein,V Pullarkat,F Sahebi,S Cohen,N Vora,K Gaal,R Nakamura,SJ Forman,

For similar diagnosis: prognosis: treatment outcome research abstracts see: diagnosis: prognosis: treatment outcome research

PUBMED ID PMID:

MEDLINE DATE:

Allogeneic hematopoietic cell transplantation following reduced intensity conditioning for treatment of myelofibrosis. Journal Published:

PUBLICATION TYPE: Research Support, N.I.H., Extr

Journal: Biology of blood and marrow transplantation : jour

VOLUME: 12

Page Numbers: 1161-8

Journal Abbreviation: Biol. Blood Marrow Transplant.

ISSN: 1083-8791

DAY: 3

MONTH: Nov

YEAR: 2006

Allogeneic hematopoietic cell transplantation following reduced intensity conditioning for treatment of myelofibrosis. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 9600628

Allogeneic hematopoietic cell transplantation following reduced intensity conditioning for treatment of myelofibrosis. Keywords Mesh Terms:

KEYWORDS: Treatment Outcome

MESH TERMS: methods

Chemical & Substance for Abstract: Allogeneic hematopoietic cell transplantation following reduced intensity conditioning for treatment of myelofibrosis. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Allogeneic hematopoietic cell transplantation following reduced intensity conditioning for treatment of myelofibrosis.

AFFILIATION: Division of Hematology/Hematopoietic Cell Transplant, City of Hope Cancer Center, Duarte, California 91010, USA. dsnyder@coh.org

Country: United States

AGENCY: United States NCI

GRANT: CA33572

ACRONYM: CA

MEDLINETA: Biol Blood Marrow Transplant

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Allogeneic hematopoietic cell transplantation following reduced intensity conditioning for treatment of myelofibrosis Related Publications

• A longitudinal study of infant feeding and obesity throughout life course.
• A popular conception of asthma in 1838.
• Allogeneic hematopoietic cell transplantation following reduced intensity conditioning for treatment of myelofibrosis.
• Aspirin, non-steroidal anti-inflammatory drugs and protection from colorectal cancer: a review of the epidemiological evidence.
• Bishydroxycoumarin (dicumarol) therapy in myocardial infarction; results of bishydroxycoumarin therapy as it is practiced in a private hospital.
• Bone marrow transplantation for hematologic malignancies.
• DFT prediction and experimental observation of substrate-induced catalyst decomposition in ruthenium-catalyzed olefin metathesis.
• Diagnostic testing in the elderly: imaging is great, but it's not the whole story.
• Experimental serum disease; a pathogenetic study.
• Helicobacter pylori and gastric cancer.
• Helicobacter pylori and gastric cancer.
• Helicobacter pylori and gastric cancer.
• Imatinib mesylate inhibits antigen-specific memory CD8 T cell responses in vivo.
• Implications of chronic heart failure on peripheral vasculature and skeletal muscle before and after exercise training.
• In children and adolescents. Emotional responses to medical illness.
• Nucleic acids and the production of antibody by plasma cells.
• Phase II Trial of a Transplantation Regimen of Yttrium-90 Ibritumomab Tiuxetan and High-Dose Chemotherapy in Patients With Non-Hodgkin's Lymphoma.
• Photo-activated azi-etomidate, a general anesthetic photolabel, irreversibly enhances gating and desensitization of gamma-aminobutyric acid type A receptors.
• Re: "Economics of radiology report editing using voice recognition technology".
• Risk of mortality and cancer incidence in Barrett's esophagus.
• Submicromolar concentrations of 4-hydroxynonenal induce glutamate cysteine ligase expression in HBE1 cells.
• Systematic reviews of the clinical effectiveness and cost-effectiveness of proton pump inhibitors in acute upper gastrointestinal bleeding.
• TDP-43 in the ubiquitin pathology of frontotemporal dementia with VCP gene mutations.
• The ADP-stimulated NADPH oxidase activates the ASK-1/MKK4/JNK pathway in alveolar macrophages.
• The good news: what we can be thankful for.
• The hidden costs of CT bioeffects.
• The impact of the Calman-Hine report on the processes and outcomes of care for Yorkshire's breast cancer patients.
• Travel times to health care and survival from cancers in Northern England.
• Use and abuse of exogenous H2O2 in studies of signal transduction.
• Valosin-containing protein and the pathogenesis of frontotemporal dementia associated with inclusion body myopathy.